Roth Capital Initiates Spark Therapeutics At Buy

Monica Gerson , Benzinga Staff Writer

February 19, 2015 8:36am Comments

Analysts at Roth Capital initiated coverage on Spark Therapeutics, Inc. (NASDAQ: ONCE) with a Buy rating.

The target price for Spark Therapeutics is set to $71.

Spark Therapeutics' shares rose 0.87% to $46.40 in after-hours trading.

Date	Firm	Action	From	To
Mar 2019	Barclays	Downgrades	Overweight	Equal-Weight
Feb 2019	Stifel Nicolaus	Downgrades	Buy	Hold
Feb 2019	Bernstein	Downgrades	Outperform	Market Perform

Posted-In: Roth Capital Initiation Analyst Ratings

Need analyst data?
Click here to see licensing options.

Stock	Firm	Action	PT
URI	Vertical Research	Initiates Coverage On	310.0
PCAR	Vertical Research	Initiates Coverage On	95.0
DE	Vertical Research	Initiates Coverage On	345.0
CNHI	Vertical Research	Initiates Coverage On	16.0
AGCO	Vertical Research	Initiates Coverage On	119.0

1	SPY, DJIA: How Trump's Stock Market Return Compares To Obama, Bush And Other...
2	TSLA: If You Bought Tesla Stock Instead Of A Model S At Launch, Here'...
3	PRPH, SENS: 33 Stocks Moving in Tuesday's Pre-Market Session
4	BNGO, BORR: 40 Stocks Moving in Wednesday's Pre-Market...
5	PLUG, FCEL: A Look At Alternative Energy Company...
6	MS, NFLX: How To Trade Netflix Ahead Of...
7	TSLA: Photos Of Tesla's Ne...

1	BMWLF, TCNNF: Florida's Medical Cannabis Market Remains 'Underpenetrated...
2	EHC, VVCIF: Cannabis Stock Gainers And Losers From January 20, 2021
3	DJIA, SPY: Here's What The Markets Did On The First Day...
4	OCX, ONC: 10 Stocks Moving In Thursday's After...
5	DMYD: Why SPAC dMY Technology Group II Surg...
6	NFLX, FUBO: Why Netflix's Soaring...
7	PG: Procter & Gamble Rais...

Market Overview